Business Description
OncoCyte Corp
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
7OC.Germany0KCC.UKOCX.USA Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.63 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.68 | |||||
| Beneish M-Score | -0.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -26 | |||||
| 3-Year EPS without NRI Growth Rate | -19.7 | |||||
| 3-Year FCF Growth Rate | -11.6 | |||||
| 3-Year Book Growth Rate | 103.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.83 | |||||
| Quick Ratio | 2.83 | |||||
| Cash Ratio | 2.51 | |||||
| Days Inventory | 12.68 | |||||
| Days Sales Outstanding | 75.58 | |||||
| Days Payable | 87.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -8.05 | |||||
| Operating Margin % | -707.4 | |||||
| Net Margin % | -788.06 | |||||
| ROE % | -82.55 | |||||
| ROA % | -39.75 | |||||
| ROIC % | -44.65 | |||||
| ROC (Joel Greenblatt) % | -636.25 | |||||
| ROCE % | -43.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.81 | |||||
| PB Ratio | 0.6 | |||||
| EV-to-EBIT | -0.28 | |||||
| EV-to-EBITDA | -0.3 | |||||
| EV-to-Revenue | 2.17 | |||||
| EV-to-FCF | -0.37 | |||||
| Earnings Yield (Greenblatt) % | -357.14 |
